PD-L1 Tecentriq by IHC

Alphabetical Test listing

PD-L1 Tecentriq by IHC-Pathology add-on

PD-L1 Tecentriq by IHC
Pathology add-on
Programmed Death-Ligand 1 (PD-L1)

The VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) triple-negative breast carcinoma (TNBC) tissue on a VENTANA BenchMark ULTRA instrument.

Evaluation is based on the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity. Primary or metastatic TNBC tissues may be submitted. 


Paraffin-embedded (FFPE) tissue block


Ambient (preferred) - indefinitely

Refrigerated – N/A

Frozen – N/A

NeoGenomics: R-NX
Mo - Fr
2 - 3 days

Immunohistochemistry (IHC)


Tissues with ≥1% IC are considered positive


PD-L1 expression in ≥1% tumor-infiltrating immune cells as determined by this assay in triple-negative breast carcinoma may be associated with increased progression-free survival in patients with advanced, locally unresectable or metastatic TNBC treated with TECENTRIQ® (atezolizumab) and chemotherapy. This test is a companion diagnostic for use of Tecentriq in certain TNBC cases.